Preview

Biomarkers of translational medicine

https://doi.org/10.17650/1726-9784-2018-17-1-6-13

Abstract

The development of new medicines is one of the priority areas of translational medicine. A significant role for biomarkers (BM) that assess the safety and efficacy of new drugs. The right choice of BM reduces the time and costs necessary for the development of drugs and transfer them to the clinic. The review is devoted to the analysis of modern scientific literature on the role of previously known and newly discovered BM in translational research. Translational BM (TBM) established during preclinical studies and are applicable at all stages of the study. TBM should have a high sensitivity and specificity, be easily measured in real time in an easily accessible biological fluids, to evaluate the same process in different species of animals (including humans), make it possible to compare the results of clinical trials with preclinical. The main role of the TBM toxicity to predict, identify and monitor the toxicity of drugs at all stages of their study. The international consortium (Predictive Safety Testing Consortium, PSTC) whose main task is the qualification of new TBM toxicity and the search for new, more advanced than existing methods for testing markers, was established. Under PSTC formed 6 working groups, each of which coordinates research for the study and selection of TBM toxicity caused by the administration of drugs in the liver, kidney, heart and blood vessels, skeletal muscle, testes. The first qualified consortium markers were 7 contained in the urine markers for preclinical studies on rats with the goal of establishing early lesions in the kidney induced by drugs. Only a small number of BM used in the study of new drugs, can be translational.

About the Authors

T. V. Osipova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
24 Kashirskoe Shosse, Moscow 115478


V. M. Bukhman
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
24 Kashirskoe Shosse, Moscow 115478


References

1. Ипатова О.М., Медведева Н.В., Арчаков А.И. и др. Трансляционная медицина – путь от фундаментальной биомедицинской науки в здравоохранение. Вестник Российской академии медицинских наук 2012;(6):1–9.

2. Пальцев М.А., Белушкина Н.Н. Трансляционная медицина – новый этап развития молекулярной медицины. Молекулярная медицина 2012;(4):1–4.

3. Шляхто Е.В. Трансляционные исследования как модель развития современной медицинской науки. Трансляционная медицина 2014;(1):5–18. DOI: 10.18705/2311-4495-2014-0-1-5-18.

4. Пономаренко Г.Н. Концепция трансляционной медицины в физиотерапии и реабилитации. Медицинский академический журнал 2013; 13(1):98–106.

5. Wang W. Global health and translational medicine: new drivers for medicine and medical sciences. J Med Med Sci 2012;3(3):126–7.

6. Homer-Vanniasinkam S., Tsui J. The continuing challenges of translational research: clinicianscientists’ perspective. Cardiol Res Pract 2012;2012:246710. DOI: 10.1155/2012/246710. PMID: 23050194.

7. Колбин А.С., Гапешин Р.А., Малышев С.М. Современные подходы к организации трансляционных исследований. Педиатрическая фармакология 2014;11(3):15–9. DOI: 10.15690/pf.v11i3.1002.

8. Feuerstein G.Z., Chavez J. Translational medicine for stroke drug discovery. The pharmaceutical industry perspective. Stroke 2009;40(3):121–5. DOI: 10.1161/STROKEAHA. 108.535104. PMID: 19064772.

9. Atkinson A.J., Colburn W., Degrutta V. et al. Biomarkers and surrogate endpoints: preferred definition and conceptual framework. Clin Pharmacol Ther 2001;69(3):89–95. DOI: 10.1067/mcp.2001.113989. PMID: 11240971.

10. Ansari D., Aronsson L., Sasor A. et al. The role of quantitative mass spectrometry in the discovery of pancreatic cancer biomarkers for translational science. J Transl Med 2014;12:87. DOI: 10.1186/1479-5876-12-87. PMID: 24708694.

11. Beger R.D., Bhattacharyya S., Yang X. et al. Translational biomarkers of acetaminophen-induced acute liver injury. Arch Toxicol 2015;89(9):1497–522. DOI: 10.1007/s00204-015-1519-4. PMID: 25983262.

12. Dennis E.H., Walker E.G., Baker A.F. et al. Opportunities and challenges of safety biomarker qualification: perspectives from the predictive safety testing consortium. Drug Dev Res 2013;74(2):112–26. DOI: 10.1002/ddr.21070.

13. DeCaprio A.P. Introduction to toxicologic biomarkers. In: Toxicologic biomarkers. Ed. by A.P. DeCaprio. New York, London: Taylor&Francis group, 2006. P. 1–12.

14. Tarrant J.M. Blood cytokines as biomarkers of in vivo toxicity in preclinical, safety, assessment: considerations for their use. Toxicol Sci 2010;117(1):4–16. DOI: 10.1093/toxsci/kfq134. PMID: 20447938.

15. Halim A.B. Biomarkers in drug development: A useful tool but discrepant results may have a major impact. In: Drug discovery and development – present and future. Ed. by I. Kapetanovič. In Tech, 2011. P. 401–30. DOI: 10.5772/27526.

16. Cosmatos D., Chow S.C. Translational medicine. Strategies and statistical methods. CRC Press, 2009. P. 1–9.

17. Zhang M., Chen M., Tong W. Is toxicogenomics a more reliable and sensitive biomarker than conventional indicators from rats to predict druginduced liver injury in humans? Chem Res Toxicol 2012;25(1):122–9. DOI: 10.1021/tx200320e. PMID: 22122743.

18. Wehling M. Development of biomarkers. In: Principles of translational science in medicine: From bench to bedside. Ed. by M. Wehling. 2nd edn. Academic Press, 2015. P. 145–9.

19. Мирошниченко И.И., Птицина С.Н. Биомаркеры в современной медико-биологической практике. Биомедицинская химия 2009;55(4):425–40.

20. Predictive approaches in drug discovery and development: Biomarkers and in vitro/in vivo correlations. Ed. by J.A. Williams, R. Lalonde, J.R. Koup, D.D. Christ. John Wiley & Sons, Inc., 2012. 408 p.

21. Sauer J.M., Walker E.G., Porter A.C. The Predictive Safety Testing Consortium: safety bio-markers collaboration, and qualification. J Med Dev Sci 2016;1(1):34–45. DOI: 10.18063/JMDS.2015.01.007.

22. Ozer J.S. A guidance for renal biomarker lead optimization and use in translational pharmacodynamics. Drug Discov Today 2010;15(3–4):142–7. DOI: 10.1016/j. drudis. 2009.12.001. PMID: 20026239.

23. Goodsaid F.M., Blank M., Dieterle F. et al. Novel biomarkers of acute kidney toxicity. Clin Pharmacol Ther 2009;86(5):490–6. DOI: 10.1038/clpt. 2009.149. PMID: 19710639.

24. Antoine D.J., Lewis P.S., Goldring C.E., Park B.K. Are we closer to finding biomarkers for identifying acute drug-induced liver injury? Biomark Med 2013;7(3):383–6. DOI: 10.2217/bmm.13.42. PMID: 23734798.

25. Campion S., Aubrecht J., Boekelheide K. et al. The current status of biomarkers for predicting toxicity. Expert Opin Drug Metab Toxicol 2013;9(11):1391–408. DOI: 10.1517/17425255.2013.827170. PMID: 23961847.

26. Wang K., Zhang S., Marzolf B. et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA 2009;106(11):4402–7. DOI: 10.1073/pnas. 0813371106. PMID: 19246379.

27. Mikaelian I., Cameron M., Dalmas D.A. et al. Nonclinical safety biomarkers of drug-induced vascular injury: current status and blueprint for the future. Toxicol Pathol 2014;42(4):635–57. DOI: 10.1177/0192623314525686. PMID: 24777748.

28. Callis T.E., Pandya K., Seok H.Y. et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest 2009;119(9):2772–86. DOI: 10.1172/JCI36154. PMID: 19726871.

29. Berridge B.R., Pettit S., Walker D.B. et al. A translational approach to detecting drug-induced cardiac injury with cardiac troponins: consensus and recommendations from the Cardiac Troponins Biomarker Working Group of the Health and Environmental Sciences Institute. Am Heart J 2009;158(1):21–9. DOI: 10.1016/j.ahj.2009.04.020. PMID: 19540388.

30. Wallace K.B., Hausner E., Herman E. et al. Serum troponins as biomarkers of drug-induced cardiac toxicity. Toxicol Pathol 2004;32(1):106–21. DOI: 10.1080/01926230490261302. PMID: 14713555.

31. O’Brien P.J. Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity. Toxicology 2008;245(3):206–18. DOI: 10.1016/j.tox.2007.12.006. PMID: 18249481.

32. Reagan W.J. Troponin as a biomarker of cardiac toxicity: past, present, and future. Toxicol Pathol 2010;38(7):1134–7. DOI: 10.1177/0192623310382438. PMID: 20884820.

33. Clements P., Brady S., York M. et al. Time course characterization of serum cardiac troponin, heart fatty acid binding protein and morphologic findings with isoproterenol-induced myocardial injury in the rat. Toxicol Pathol 2010;38(5):703–14. DOI: 10.1177/0192623310374969. PMID: 20585145.

34. Moffit J.S., Her L.S., Mineo A.M. et al. Assessment of inhibin B as a biomarker of testicular injury following administration of carbendasim, cetrorelix, or 1,2-dibromo-3-chloropropane in Wistar Han rats. Birth Defects Res B Dev Reprod Toxicol 2013;98(1):17–28. DOI: 10.1002/bdrb.21045. PMID: 23364888.

35. Stewart J., Turner K.J. Inhibin B as a potential biomarker of testicular toxicity. Cancer Biomark 2005;1(1):75–91. DOI: 10.3233/CBM-2005-1109. PMID: 17192034.

36. Roberts R.A., Aschner M., Calligaro D. et al. Translational biomarkers of neurotoxicity: a Health and Environmental Sciences Institute perspective on the way forward. Toxicol Sci 2015;148(2):332–40. DOI: 10.1093/toxsci/kfv188. PMID: 26609132.

37. Биомаркеры и оценка риска: концепции и принципы. Совместное издание программы ООН по окружающей среде, международной организации труда и Всемирной организации здравоохранения. Выпущено издательством «Медицина» по поручению МЗ РФ. Женева: Всемирная организация здравоохранения, 1996. 54 с.

38. O’Callaghan J.P., Sriram K. Glial fibrillary acidic protein and related glial proteins as biomarkers of neurotoxicity. Expert Opin Drug Saf 2005;4(3):433–42. DOI: 10.1517/14740338.4.3.433. PMID: 15934851.


Review

For citations:


Osipova T.V., Bukhman V.M. Biomarkers of translational medicine. Russian Journal of Biotherapy. 2018;17(1):6-13. (In Russ.) https://doi.org/10.17650/1726-9784-2018-17-1-6-13

Views: 619


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1726-9784 (Print)
ISSN 1726-9792 (Online)